The DOI matches its Crossref record; 9 of the 10 references it cites were found in a registry or an index.
An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
Open accessPublished version of a preprint
Abstract
The world is entering a new era of the COVID-19 pandemic in which there is an increasing call for reliable antibody testing. To support decision making on the deployment of serology for either population screening or diagnostics, we present a detailed comparison of serological COVID-19 assays. We show that among the selected assays there is a wide diversity in assay performance in different scenarios and when correlated to virus neutralizing antibodies. The Wantai ELISA detecting total immunoglobulins against the receptor binding domain of SARS CoV-2, has the best overall characteristics to detect functional antibodies in different stages and severity of disease, including the potential to set a cut-off indicating the presence of protective antibodies. The large variety of available serological assays requires proper assay validation before deciding on deployment of assays for specific applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the Wantai ELISA is a qualitative assay, a ratio of >10 has previously been shown to correspond to virus neutralization (44).”
From SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients (2021) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H., & Lipsitch, M. (2020) · Science · doi:10.1126/science.abb5793 · Cited by 2,611
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614
Self-citationEstimating the effects of non-pharmaceutical interventions on COVID-19 in Europe
Flaxman, S. R., Mishra, S., Gandy, A., Unwin, H. J. T., Mellan, T. A., Coupland, H., Whittaker, C., Zhu, H., Berah, T., Eaton, J. W., et al. (2020) · Spiral (Imperial College London) · doi:10.25561/77731 · Cited by 632
Evaluation of nine commercial SARS-CoV-2 immunoassaysPreprint
Lassaunière, R., Frische, A., Harboe, Z. B., Nielsen, A. C. Y., Fomsgaard, A., Krogfelt, K. A., & Jørgensen, C. S. (2020) · medRxiv · doi:10.1101/2020.04.09.20056325 · Cited by 319
MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015
Choe, P. G., Perera, R. A. P. M., Park, W. B., Song, K.-H., Bang, J. H., Kim, E. S., Kim, H. B., Ko, L. W. R., Park, S. W., Kim, N.-J., et al. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2307.170310 · Cited by 227
Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward
Bryant, J. E., Azman, A. S., Ferrari, M. J., Arnold, B. F., Boni, M. F., Boum, Y., Hayford, K. T., Luquero, F. J., Mina, M. J., Rodríguez-Barraquer, I., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abc6347 · Cited by 142
Herd immunity is not a realistic exit strategy during a COVID-19 outbreakPreprint
Slot, E., Hogema, B. M., Reusken, C. B. E. M., Reimerink, J. H. J., Molier, M., Karregat, J. H. M., IJlst, J., Novotny, V. M. J., van Lier, R. A. W., & Zaaijer, H. L. (2020) · Research Square · doi:10.21203/rs.3.rs-25862/v1 · Cited by 55
Cited by
Sorted by citations
Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans
Munnink, B. B. O., Sikkema, R. S., Nieuwenhuijse, D. F., Molenaar, R. J., Münger, E., Molenkamp, R., van der Spek, A. N., Tolsma, P., Rietveld, A., Brouwer, M., et al. (2020) · Science · doi:10.1126/science.abe5901 · Cited by 1,116
Self-citationAntibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940
Humoral Immune Response to SARS-CoV-2 in Iceland
Gudbjartsson, D. F., Norddahl, G. L., Melsted, P., Gunnarsdottir, K., Holm, H., Eythorsson, E., Arnthorsson, A. O., Helgason, D., Bjarnadottir, K., Ingvarsson, R. F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026116 · Cited by 903
van Kampen, J. J. A., van de Vijver, D. A. M. C., Fraaij, P. L. A., Haagmans, B. L., Lamers, M. M., Okba, N., van den Akker, J. P. C., Endeman, H., Gommers, D. A. M. P. J., Cornelissen, J. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20568-4 · Cited by 838
Self-citationModel-informed COVID-19 vaccine prioritization strategies by age and serostatus
Bubar, K. M., Reinholt, K., Kissler, S. M., Lipsitch, M., Cobey, S., Grad, Y. H., & Larremore, D. B. (2021) · Science · doi:10.1126/science.abe6959 · Cited by 775
Metadata
- Authors
- GeurtsvanKessel, C. H., Okba, N. M. A., Igloi, Z., Bogers, S., Embregts, C. W. E., Laksono, B. M., Leijten, L., Rokx, C., Rijnders, B., Rahamat-Langendoen, J., van den Akker, J. P. C., van Kampen, J. J. A., van der Eijk, A. A., van Binnendijk, R. S., Haagmans, B., & Koopmans, M.
- Affiliations
- Erasmus MC (NL)
- Radboud University Medical Center (NL)
- Corresponding author
- GeurtsvanKessel, Corine H.
- ORCID
- Venue
- Nature Communications
- Published
- 2020-07-06
- Volume
- 11
- Issue
- 1
- Pages
- 3436-3436
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC7338506
- OpenAlex
- W3039328844
- Cited by
- 361
- References
- 10
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 15 · 2023: 33 · 2022: 66 · 2021: 165 · 2020: 68
- FWCI
- 10.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Nature Communications (publishedVersion, cc-by)
- medRxiv (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Radboud Repository (Radboud University) (submittedVersion)
- Rivm Repository (Netherlands National Institute for Public Health and the Environment) (submittedVersion)
- Rivm (National Institute for Public Health and the Environment) (submittedVersion)
- Rivm (National Institute for Public Health and the Environment) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- COVID-19 pandemic, SARS-CoV-2, serological assays, antibody detection, ELISA, receptor binding domain, virus-neutralizing antibodies, assay validation, diagnostic accuracy, exposure assessment, mass screening, disease severity
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Testing, Antibodies, Viral, Enzyme-Linked Immunosorbent Assay, Humans, Luminescent Measurements, Neutralization Tests, Pneumonia, Viral, Sensitivity and Specificity, Serologic Tests, Coronavirus Infections, Clinical Laboratory Techniques, Antibodies, Neutralizing, High-Throughput Screening Assays, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
